ERBB2 and inflammatory breast carcinoma: Among these, nearly half (44%) exhibited a markedly lower mutation rate in IP5, including TP53, ERBB2/4, MAP3K4, BRCA1, and PIK3CA. Further cases are needed to verify whether the heterogeneous immunogenicity of IBC is attributable to driver gene mutation signatures, as suggested in prior studies22.